Mcl-1 as a "barrier" in cancer treatment: Can we target it now?

Area of Science:

• Molecular Biology
• Cancer Research
• Pharmacology

Background:

• Mcl-1, an anti-apoptotic protein in the Bcl-2 family, plays a key role in cancer cell survival and tumor progression.
• Mcl-1 overexpression contributes to resistance against chemotherapy, making it a significant therapeutic target.

Purpose of the Study:

• To review diverse strategies for inhibiting Mcl-1, a critical target in cancer therapy.
• To discuss both indirect (downregulation) and direct (protein-protein interaction blocking) inhibition approaches.
• To highlight challenges and progress in developing Mcl-1 inhibitors, including BH3-mimetics and co-targeting strategies.

Main Methods:

• Review of existing literature on Mcl-1 inhibition mechanisms.
• Discussion of indirect inhibition via proteasomal degradation, translation, and transcription blockage.
• Overview of direct inhibition through blocking protein-protein interactions with pro-apoptotic proteins.
• Presentation of co-targeting strategies involving Mcl-1 and other proteins like CDKs.

Main Results:

• Multiple avenues for Mcl-1 inhibition exist, including targeting its synthesis or degradation.
• Direct inhibition using BH3-mimetics shows promise and is under clinical evaluation.
• Co-targeting Mcl-1 with other proteins offers potential synergistic effects in cancer treatment.

Conclusions:

• Inhibiting Mcl-1 is a promising strategy for overcoming chemoresistance and treating cancer.
• Developing selective and effective Mcl-1 inhibitors faces significant challenges.
• Further research into direct and indirect inhibition, as well as combination therapies, is crucial for advancing Mcl-1 targeted cancer treatment.